君實生物(01877.HK):臨港生產基地有序復工復產 已投入商業化生產
君實生物(01877.HK)表示,上海臨港生產基地作爲臨港新片區內重點生物醫藥產業化基地,在被列入第一批覆工復產白名單後已迅速啓動復工安排,目前已完成藥品生產環境恢復,並啓動多款商業化和臨牀階段產品的大規模生產,將爲患者用藥的持續供應保駕護航。
該生產基地佔地80畝,總建築面積7萬平米,一期項目生產規模達3萬升。公司表示,經工作組研判,已優先安排生產基地、重點項目、後勤保障、研發中心人員分批逐步返回崗位,在確保防控安全的前提下進行閉環管理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.